Loading clinical trials...
Loading clinical trials...
A Phase I, Open-Label, Multicenter, Dose Escalation and Cohort Expansion Study of SPYK04 as Monotherapy in Patients With Locally Advanced or Metastatic Solid Tumors
Conditions
Interventions
SPYK04
Locations
15
United States
Arizona Oncology
Tucson, Arizona, United States
Rocky Mountain Cancer Centers
Lone Tree, Colorado, United States
Minnesota Oncology
Minneapolis, Minnesota, United States
Rhode Island Hospital
Providence, Rhode Island, United States
MD Anderson Cancer Center
Houston, Texas, United States
Texas Oncology
Tyler, Texas, United States
Start Date
September 10, 2020
Primary Completion Date
September 30, 2026
Completion Date
September 30, 2026
Last Updated
July 14, 2025
NCT06716138
NCT06307795
NCT05581004
NCT06974812
NCT06107686
NCT05205109
Lead Sponsor
Chugai Pharmaceutical
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions